GlassScriptPhysician profile
Prevesh K Rustagi
NPI 1245237411
$63,524.47
in general payments reported to CMS, 2019-2025
34 companies · $2,305 in 2025
The $2,305 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,589 · 2020: $1,060 · 2021: $1,666 · 2022: $11K · 2023: $21K · 2024: $21K · 2025: $2,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $8,167 · Honoraria: $2,275 · Travel and Lodging: $2,257 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,125.00 |
| Food and Beverage | $8,167.27 |
| Honoraria | $2,275.00 |
| Travel and Lodging | $2,257.45 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $26,259.51 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $15,069.79 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Ironshore Pharmaceuticals INC. | $10,943.11 | 2019-2024 | Jornay Pm |
| Lundbeck LLC | $2,098.75 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $989.37 | 2020-2025 | Caplyta |
| Corium, LLC | $869.72 | 2021-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $846.49 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $718.91 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $702.85 | 2019-2025 | Trintellix |
| Abbvie INC. | $677.48 | 2021-2025 | Vraylar |
| Alkermes, INC. | $614.30 | 2021-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $541.12 | 2019-2024 | Adzenys Xr-Odt |
| Adlon Therapeutics L.P. | $464.93 | 2019-2021 | |
| Tris Pharma INC | $463.49 | 2019-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $273.69 | 2020-2025 | Xelstrym |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $217.35 | 2022-2025 | Quviviq, Quviviq |
| Collegium Pharmaceutical, INC. | $206.81 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $198.70 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $195.20 | 2019-2025 | Fanapt, Hetlioz |
| Eisai INC. | $188.57 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $131.31 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $119.46 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $94.58 | 2019-2022 | |
| Shire North American Group INC | $90.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $87.50 | 2022 | |
| Harmony Biosciences LLC | $81.64 | 2023-2024 | Wakix |
| Merck Sharp & Dohme LLC | $75.46 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $59.22 | 2025 | Relexxii |
| Almatica Pharma LLC | $55.03 | 2022-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $51.07 | 2019-2025 | Spravato |
| Arbor Pharmaceuticals, INC. | $44.92 | 2019 | |
| Allergan, INC. | $42.37 | 2020 | |
| Owp Pharmaceuticals, INC. | $38.00 | 2019-2023 | Subvenite, Lamotrigine |
| Neuronetics, INC. | $13.52 | 2024 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prevesh Rustagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.